Posted Date: January 4, 2017
The FDA gives conditional approval for a new drug for canine lymphoma.
The U.S. Food & Drug Administration announced the conditional approval of a new drug for the treatment of lymphoma in dogs. The drug is called Tanovea-CA1 and is given via injection. The conditional approval is valid for one year while the drug manufacturer, VetDC, works on collecting "substantial evidence of effectiveness" for the FDA to gain full approval.
Known side effects of the drug from clinical tests are a lowered white blood cell count, vomiting, loss of appetite, diarrhea, weight loss, lethargy and skin problems including scabs, sores and some hair loss.
According to the National Canine Cancer Foundation, malignant lymphoma (lymphosarcoma) is one of the most common forms of tumors found in dogs and accounts for between seven to 24% of all canine new tissue formations and 83% of canine hematopoietic malignancies. Dogs that tend to get lymphosarcoma the most are middle aged to senior dogs (approximately six- to nine-years-old) and breeds with a higher tendency for this cancer are Airedales, Boxers, Bull Dogs, Bull Mastiffs, Basset Hounds, Saint Bernards, and Scottish Terriers.
For more information, here is the official press release from the FDA, and consult your veterinarian.